{"id":"NCT01126190","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel","officialTitle":"A Randomized, Double-Blind, Active Comparator, Non-Inferiority Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim in Subjects With Breast Cancer Receiving Myelosuppressive Chemotherapy (Doxorubicin/Docetaxel), Followed by a Single-Arm, Open-Label Phase of Subcutaneously Administered Neugranin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06-30","primaryCompletion":"2012-02-29","completion":"2012-02-29","firstPosted":"2010-05-19","resultsPosted":"2023-03-28","lastUpdate":"2023-03-28"},"enrollment":381,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Chemotherapy-induced Neutropenia"],"interventions":[{"type":"BIOLOGICAL","name":"Neugranin","otherNames":["Balugrastim"]},{"type":"BIOLOGICAL","name":"Pegfilgrastim","otherNames":["Neulasta"]},{"type":"DRUG","name":"Chemotherapy","otherNames":["Doxorubicin/Docetaxel"]}],"arms":[{"label":"Double-Blind Phase: Pegfilgrastim","type":"ACTIVE_COMPARATOR"},{"label":"Double-Blind Phase: Neugranin 40 mg","type":"EXPERIMENTAL"},{"label":"Open-Label Phase: Neugranin 40 mg","type":"EXPERIMENTAL"}],"summary":"Determination of the effect of neugranin on the duration and severity of severe neutropenia in participants receiving doxorubicin in combination with docetaxel.","primaryOutcome":{"measure":"Double-Blind Phase: Duration of Severe Neutropenia in Cycle 1","timeFrame":"Cycle 1 (cycle length = 21 days)","effectByArm":[{"arm":"Double-Blind Phase: Pegfilgrastim","deltaMin":1,"sd":1.08},{"arm":"Double-Blind Phase: Neugranin 40 mg","deltaMin":1.1,"sd":1.13}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":59,"countries":["Bulgaria","Romania","Russia","Serbia","Ukraine"]},"refs":{"pmids":["24485296"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":150},"commonTop":["Alopecia","Nausea","Neutropenia","Asthenia","Leukopenia"]}}